Shifting The T1D Paradigm: Early Detection, Disease Modification, and Beta-Cell Preservation

Wednesday, July 15, 2026

4:00 PM – 5:00 PM PT
5:00 PM – 6:00 PM MT
6:00 PM – 7:00 PM CT
7:00 PM – 8:00 PM ET

Program Overview

With the advent of disease-modifying therapies to delay progression of type 1 diabetes (T1D), as well as their potential application of these therapies in newly diagnosed T1D, there is an increased emphasis on presymptomatic screening, staging, and monitoring—representing a true paradigm shift in how we address the disease. This proactive approach is paramount in pediatric populations, who are at higher risk for progression after testing positive for islet autoantibodies. This symposium will provide an overview of the practical considerations for early detection of T1D and the application of disease-modifying therapy for delaying disease progression in pediatric patients, while also exploring emerging treatment approaches aimed at preserving beta cell function in newly diagnosed T1D.

Target Audience

This activity is designed to meet the educational needs of pediatric endocrinologists.

Learning Objectives

Upon completion of this activity, attendees will have improved ability to:

Implement risk-based screening approaches to facilitate timely identification of presymptomatic T1D
Analyze T1D screening results to determine disease stage and inform appropriate monitoring and referral decisions
Develop individualized treatment strategies that incorporate disease-modifying therapies to delay T1D progression in eligible patients
Recognize the importance of beta-cell preservation on T1D prognosis and outcomes
Review emerging approaches aimed at beta cell preservation & their potential future application in new-onset T1D

Joint Accreditation Statement

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement

Med Learning Group designates this enduring activity for a maximum of 3.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Nurses (ANCC) Credit Designation

Med Learning Group designates this activity for a maximum of up to 3.5 ANCC contact hours.

Commission on Dietetic Registration (CDR) Credit Designation

Med Learning Group designates this activity for a maximum of 3.5 CPEU.

ACCME Innovation Partner

Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.

PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.

Disclosure Policy Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Disclosure of Relevant Financial Relationships

Faculty Member	Disclosures
Daniel DeSalvo, MD	Consulting fees: Dexcom, Insulet, Mannkind, Sanofi
Roshanak Monzavi, MD	Consulting fees: Sanofi and MannKind Contracted research: Insulet, Medtronic, MannKind

All relevant financial relationships have been mitigated.

Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
Shpetim Karandrea, PhD, Medical Director for Med Learning Group has nothing to disclose.
Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Dominique Barton, BS, BSN, has nothing to disclose.
A medical reviewer from CME Peer Review LLC, has nothing to disclose.
Marissa Mays-Verman, Program Director for Med Learning Group, has nothing to disclose.
Alexis Klinger, Program Manager for Med Learning Group, has nothing to disclose.
Melanie Grau, Program Coordinator for Med Learning Group, has nothing to disclose.

Disclosure Of Unlabeled Use

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

Method of Participation

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

Disclaimer

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at info@medlearninggroup.com

This activity is provided by Med Learning Group.

This activity is supported by an educational grant from Sanofi US.

Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Release date: July 15, 2026
Expiration date: July 15, 2027
Estimated time to completion: 1.5 hours